Nonalcoholic fatty liver disease is now recognized as the most common liver disease in the United States, with a prevalence of approximately 5% in the general population and up to 25% to 75% in patients with obesity and type II diabetes mellitus. Nonalcoholic fatty liver disease is a clinicopathologic syndrome with a wide spectrum of histologic abnormalities and clinical outcomes. Hepatic steatosis has a benign clinical course. In contrast, nonalcoholic steatohepatitis (NASH) may progress to cirrhosis and liverrelated death in 25% and 10% of patients, respectively. Cases occur most commonly in obese, middle-aged women with diabetes. However, NASH may also occur in children and normalweight men with normal glucose and lipid metabolism. The pathophysiology involves two steps. The first is insulin resistance, which causes steatosis. The second is oxidative stress, which produces lipid peroxidation and activates inflammatory cytokines resulting in NASH. Liver biopsy provides prognostic information and identifies NASH patients who may benefit from therapy. Treatment consists of managing the comorbidities: obesity, diabetes, and hyperlipidemia. Although antioxidant therapy with vitamin E is often used, ursodeoxycholic acid is the only drug that has shown benefit and is the most promising of the drugs currently being investigated. Future therapies will depend on a greater understanding of the pathophysiology and should focus on diminishing fibrosis.
BACKGROUND
T he term nonalcoholic steatohepatitis (NASH) was first used by Dr. Ludwig and colleagues in 1980 1 to describe a previously recognized clinicopathologic syndrome. 2 The original syndrome described predominantly obese, diabetic women, who denied alcohol use, but in whom the hepatic histology was consistent with alcoholic hepatitis. The pathologic analysis revealed fibrosis (15% of patients had cirrhosis); macrovesicular fat, focal hepatocyte necrosis with a mixed inflammatory infiltrate and Mallory hyaline. More recent studies emphasize that NASH is becoming more prevalent with increasingly adverse clinical outcomes. [3] [4] [5] [6] However, as shown in Figure 1 , it is important to emphasize that NASH should be considered only one type of a larger spectrum of nonalcoholic fatty liver disease (NAFLD), which includes fat alone and fat with nonspecific inflammation, in addition to NASH. 6, 7 With this in mind, the term NASH should be restricted to cases that meet strict criteria that are required for the diagnosis of alcoholic hepatitis. 3, 8 Although NAFLD is a common disease that is associated with a wide variety of causes, [9] [10] [11] such as drugs, surgical procedures, and a number of miscellaneous disorders (Table 1) , this review will concentrate on the primary form of NAFLD, which is associated with insulin resistance 12 and its related diseases such as type II diabetes mellitus and obesity. 9, 13 PREVALENCE Nonalcoholic fatty liver disease is a common problem and has now been reported on all continents 8 except Antarctica. The true prevalence of NAFLD remains to be established. However, in general population studies, screening with ultrasound [14] [15] [16] [17] or computed tomography 18 suggest a prevalence ranging between 16% and 23%. Although such studies cannot differentiate between the different histologic forms of NAFLD, postmortem analysis of livers from pa-tients who died randomly from automobile 19 or air crashes 20 report prevalence rates of approximately 20% and 3% for steatosis alone and NASH, respectively. However, the prevalence of NAFLD is higher in certain subgroups and may approach 75% in patients with obesity, 17 defined as a body mass index 30 or more. The importance of this observation is emphasized by the fact that in the United States, the prevalence of obesity has increased from 15% to 25% in women and from 10% to 20% in men during the 30-year epoch between 1961 and 1991 21 such that 22.5% of the U.S. population is now obese. 22 Furthermore, current trends predict that the prevalence of obesity could reach 40% by the year 2025.
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NATURAL HISTORY
Before discussing the natural history of the different histologic forms of NAFLD, two factors (Table 2) , which vary among the published trials, should be discussed because they may influence our understanding of NAFLD. The first are the histologic criteria used to diagnose NASH. Although some studies require only steatosis plus nonspecific inflammation, 4, 5, [24] [25] [26] other studies require a more vigorous definition of NASH, 27 which includes hepatocyte ballooning degeneration, fibrosis, and neutrophilic inflammation with or without Mallory hyaline. 1, 4, 6 This issue is important because the natural history of NAFLD varies according to the histologic type. Patients with hepatic steatosis alone 6, 28 or steatosis with nonspecific inflammation 6 appear to have a benign clinical course. In contrast, 27% of patients with NASH have progression of fibrosis on follow-up biopsies and an additional 19% advance to cirrhosis when followed for up to 19 years. [3] [4] [5] Recent studies also suggest that NAFLD may be the cause of cryptogenic cirrhosis. [29] [30] [31] [32] Of note, the degree of steatosis may decrease or the steatosis may even disappear completely as cirrhosis develops. 4, 29 A number of risk factors have been identified as predictors for the development of progressive fibrosis and cirrhosis in patients with NAFLD. 6, 24 The presence of either obesity and/or type II diabetes mellitus are the strongest predictors of fibrosis. 6, 24 Age is also a risk factor for cirrhosis, 6, 24, 33 which reflects the duration of time that steatosis is at risk for a subsequent "second hit" injury 34 that initiates fibrosis. Finally, as in viral hepatitis, an alanine aminotransferase/aspartate aminotransferase >1 indicates a fibrotic stage of NAFLD. 24, 35 Emphasizing the importance of this issue, different approaches to the histologic interpretation have been proposed, 7, 36 and the reliability of the histologic interpretation of NAFLD confirmed. 7 Although there is no consensus currently regarding nomenclature and histologic categorization of this disease, a recent study 6 examined the natural history of NAFLD among four different histologic forms. This retrospective study of 136 patients, 98 of whom had complete data available at a 10-year follow-up, separated NAFLD into four histologic types: fat alone (type 1), fat + nonspecific inflammation (type 2), fat + ballooning degeneration (type 3), and fat + fibrosis (type 4). As shown in Figure 2 , cirrhosis developed predominantly in type 3 (fat + ballooning degeneration) and 4 (fat + fibrosis), occurring in 21% and 28% of these histologic types, respectively. These results are very similar to the prevalence of cirrhosis reported in three previous studies. [3] [4] [5] Death was increased in the patients with more severe histologic forms (types 3 and 4). During a 20-year period, there was an 11% death rate in the type 3 and type 4 non-NAFLD patients as compared with a crude adjusted death rate of 9.5/100,000 for the general population. 37 Furthermore, liver-related deaths were the second most common cause of death in NAFLD, with rates equaling those from coronary artery disease and trailing only cancer-related deaths. This study 6 also confirmed the benign clinical course in the histologic types of fat alone and fat plus nonspecific inflammation. Of particular importance is the fact that this study (excluded hepatitis C and iron) as etiologic factors.
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ALCOHOL USE
The second issue is the nonuniformity in the exclusion limit of alcohol use among the published trials displayed in Table 2 . Related to this is the question, "What do the words nonalcoholic in NAFLD exactly mean?" By its very definition, the diagnosis of NAFLD cannot be made in the setting of excessive alcohol consumption. However, as shown in Table 2 , there is no consensus among investigators as to what is an excessive amount of alcohol, 39, 40 especially in the setting of preexisting fatty liver. Table 2 displays the weekly amount of alcohol consumption that excluded patients from the published reports of NAFLD. 1, 2, [4] [5] [6] [24] [25] [26] 41 As can be seen, there is a wide range of alcohol consumption allowed in these studies of "nonalcoholic" fatty liver disease. This is an important issue for a number of reasons: first, it has been estimated that 20 g/d of alcohol can cause hepatic steatosis; 39, 42 second, the hepatotoxic dosage of alcohol in the general population can be as low as 20 g/d in women and 40 g/d in men; 43, 44 third, hepatic steatosis is a risk factor for alcohol-induced liver injury; 45, 46 and finally, the hepatotoxic dosage of alcohol in the setting of preexisting concurrent hepatic steatosis is unknown. 47 
CLINICAL CHARACTERISTICS
The patient demographics from a number of published trials are displayed in Table 3 . The average age varies between 47 and 53. Cases occur more commonly in women (65-83%), and there is a high prevalence of obesity (39-93%) and type II diabetes mellitus (21-55%). The presence of hyperlipidemia is more variable. Of considerable concern are the increasing reports of NAFLD in children who have mean ages ranging between 12 and 14 and who are predominantly male and more likely to be obese, but less likely to be diabetic, than adult NAFLD patients. 48, 49 LABORATORY TESTS Although most patients are asymptomatic (77%), some patients have a variety of symptoms including right upper quadrant pain, fatigue, or abdominal discomfort. 8 Typically, patients are found incidentally to have abnormal liver function tests or hepatomegaly when being evaluated for other conditions. 8 The most common abnormality in liver function tests is a 2-to 3-fold elevation in the alanine aminotransferase and aspartate aminotransferase, although rarely these can be 10-to 15-fold elevated. 8 The aspartate aminotransferase/alanine aminotransferase ratio is usually <1, which can help distinguish NAFLD from alcoholic-related liver disease. 8, 35 When the aspartate aminotransferase/alanine aminotransfer-
FIG. 2.
Among the different types of nonalcoholic fatty liver disease (NAFLD): fat alone (type 1), fat + nonspecific inflammation (type 2), fat + ballooning degeneration (type 3) and fat + fibrosis (type 4), cirrhosis was more prevalent in patients with type 3 (ballooning degeneration) and type 4 (fibrosis) NAFLD, cirrhosis was more prevalent in patients with types 3 and 4. 
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ase ratio is >1 in NAFLD, it suggests an advanced fibrotic stage of disease. 6, 24 As expected, the alkaline phosphatase and gamma-glutamyl transferase may be increased 2-to 3-fold in more than 50% of the cases. Serum bilirubin and albumin are usually normal, unless the disease has advanced to cirrhosis. 8 Hepatic fat is often increased in other liver diseases 50 including Wilson's disease, autoimmune liver disease, galactosemia, hepatitis C infection, and alcoholic liver disease. Therefore, these diseases as well as the secondary causes of NAFLD listed in Table 1 must be excluded before a diagnosis of primary NAFLD can be made.
EXCLUSION OF OTHER DISEASES
Although two studies have found serum ferritin and transferrin saturation to be increased in approximately 50% and 10% of these patients, respectively, 5,24 a number of studies have found no evidence of increased hepatic iron. 1, 5, 6, 24, 38 Testing for the HFE gene 51 may be necessary in those patients with serologic evidence of iron overload.
PATHOPHYSIOLOGY Etiology of Hepatic Steatosis
A general schematic for the development of NAFLD is provided in Figure 3 . It is now "generally" recognized that insulin resistance is an essential pathophysiologic factor in the development of NAFLD. 8, 12, 52, 53 In fact, hepatic steatosis has now been proposed as a feature of the insulin resistance syndrome 13 along with type II diabetes mellitus, central (visceral) obesity, hyperlipidemia, and hypertension.
Recent clamp studies 52, 53 have demonstrated peripheral resistance to insulin's normal suppression of lipolysis, resulting in increased circulating levels of free fatty acids. It has been proposed that this influx of fatty acids to the liver combined with potential alterations in their hepatic metabolism (including increased triglyceride synthesis, decreased triglyceride export, or decreased fatty acid oxidation) results in hepatic steatosis. 9 Although these proposed alterations in the hepatic metabolism of fatty acids are reasonable, it should be emphasized that they are-as yet-unproven. Once developed, this hepatic steatosis may take two divergent histologic forms, which have very different clinical outcomes (Fig. 3) .
Hepatic Steatosis
Steatosis alone is thought to be the most common form NAFLD and is considered "benign." Two studies 6, 28 confirm that patients with steatosis alone have a benign clinical course without histologic clinical progression when followed for up to 19 years. However, this "benign" steatosis is not quiescent. There is activation of hepatic stellate cells, 54 stimulation of apoptotic proteins 55 and upregulation of uncoupling protein, 56 which have the potential to cause fibrosis, cell death, and a deficiency in intracellular adenosine triphosphate, 57 respectively. Despite these insidious processes, hepatic histology (other than steatosis) and function are normal, which indicates that counter-regulatory cytoprotective processes must be implicated as a means for maintaining hepatic health in the face of this cellular stress.
NONALCOHOLIC STEATOHEPATITIS
Nonalcoholic steatohepatitis is the more advanced form of NAFLD and has the histologic findings of sinusoidal/pericellular fibrosis, ballooning degeneration, and polymorphonuclear infiltration with or without Mallory hyalin. Cirrhosis develops in approximately 25% of these patients and up to 10% to 12% may experience liver-related deaths within a 10-year period. 6 It is unclear why only approximately 15% to 20% of patients with NAFLD develop NASH. However, it has been proposed that lipid-laden hepatocytes act as a reservoir of hepatotoxic agents and are most susceptible to a second-hit injury 34, 58 by compounds such as endotoxin, cytokines, and environmental toxins. 8, 59, 60 The proposed mechanisms of hepatocyte injury in NASH have been reviewed recently. 61, 62 Based on a large amount of animal data 63 and nascent human data, 52, 64, 65 it appears that NASH is associated with oxidative stress and lipid peroxidation. The oxidative stress results from increased ␤-oxidation of short-, medium-, and long-chain fatty acids by mitochondria and very long-chain fatty acid oxidation by peroxisomes and -oxidation of long and very long chain fatty acids by the cytochrome P450 CYP2E1 and CYP4A system. 66 These oxidative processes produce free electrons, H 2 O 2 , and reactive oxygen species while depleting the potent antioxidants glutathione 67 and vitamin E. 68, 69 Oxidative stress also stimulates the synthesis of several cytokines through both the upregulation of transcription by nuclear translocation of nuclear factor KB (NF-K9) 70 and the byproducts of lipid peroxidation-malondialdehyde, and   FIG. 3 . The pathophysiology of nonalcoholic fatty liver disease involves insulin resistance, which causes hepatic steatosis, a process enhanced in patients with type II diabetes mellitus and/or obesity. Once developed, hepatic steatosis may remain in the benign state or progress to nonalcoholic steatohepatitis.
4-hydroxynonenal-hydroxynonenal. 71 The combination of these events causes hepatocyte injury through lipid peroxidation and the stimulation of cytokine production as displayed in Figure 4 .
Hepatocyte cell death may occur via the direct effects of reactive oxygen species and tumor necrosis factor on apoptosis, 72, 73 as well as through FAS ligand-mediated fratricidal killing. 62 Hydroxynonenal, malondialdehyde, and transforming growth factor ␤ all stimulate both collagen synthesis by hepatic stellate cells leading to fibrosis 74, 75 and the condensation/cross-linking of intermediate cytokine filaments leading to Mallory hyalin. 76, 77 Finally, both hydroxynonenal and interleukin-8 are chemoattractants for neutrophils, 78, 79 which induce their own pathophysiologic cascade.
The other proposed pathophysiologic mechanism for the development of NASH involves increased delivery of portal-derived hepatotoxins to a sensitized fatty liver. Animal studies have demonstrated that fatty livers are extremely vulnerable to toxicity from endotoxin/lipopolysaccharide and ethanol feeding. 59, [80] [81] [82] This concept is supported from human data showing bacterial overgrowth and endogenous alcohol production in patients with NAFLD. [83] [84] [85] However, even if this mechanism were operative, the resultant liver injury would likely be mediated through cytokine-induced oxidative stress 86 and involve mechanisms displayed in Figure 4 .
A number of recent observations link the development of fibrosis in NAFLD with leptin, 61 a satiety hormone that inhibits feeding behavior and increases energy expenditure. 87 The genetically leptin-deficient ob/ob mouse model, 81 which has a metabolic profile similar to obese human patients with type 2 diabetes except for leptin deficiency, does not develop fibrosis even when fed the fibrogenic methionine choline-deficient diet. 67 Activated stellate cells produce leptin, 88 and leptin blood levels, which are higher in women, 89 correlate with the stage of fibrosis in hepatitis C. 61 These observations raise the possibility that leptin might be an important factor that modulates hepatic fibrogenesis in NASH.
TREATMENT
Because NAFLD is usually associated with the comorbid conditions of type II diabetes, obesity and/or hypertriglyceridemia, treatment of these comorbid conditions has been considered essential in the management of these patients. 90 However, the benefits of this strategy have been inconsistent.
Weight Loss
A number of studies in both adults [91] [92] [93] [94] and children [95] [96] [97] indicate that NAFLD may improve with weight reduction. The major outcome measure that improved with weight loss were serum transaminases and radiologic evaluation of hepatic steatosis. This improvement occurred with as little as a 10% decrease in body weight. The majority of the 32 patients who had histologic evaluation after weight loss demonstrated a decrease in steatosis, but only 16 (or 50%) had improvement in the degree of fibrosis. This latter point is important because two other studies, 98, 99 which also evaluated hepatic histology after weight loss in NAFLD, found increased fibrosis despite diminished steatosis. This seemingly paradoxical finding in the latter two studies appears related to the different rates and degrees of weight loss among studies.
Rapid weight loss may actually increase the flux of free fatty acids to the liver resulting in lipid peroxidation at the same time that hepatic steatosis is diminishing. Therefore, gradual weight loss (0.45-0.9 kg/wk) with an overall goal of 10% weight loss is recommended as a safe and effective clinical strategy, 90 especially in patients who are 30% overweight. 100 Appetite-suppressing medications are now available and are sometimes used in weight management programs. However, whether the risk-to-benefit ratio of these appetitesuppressing medications justifies their use in NAFLD is unclear. 90, 91 However, if used, they should be used judiciously and only as part of an overall management of these patients.
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Management of Diabetes and Hyperlipidemia
In addition to weight management, patients with type II diabetes and/or hyperlipidemia should have the laboratory control of these metabolic comorbidities optimized, which is consistent with the current standard of care. For patients with diabetes with NAFLD, troglitazone, which is one of the new class of drugs-the thiazolidinediones-that reduce circulating insulin levels, triglycerides, and free fatty acids, has recently been shown to improve serum transaminases, but had little or no effect on hepatic histology. 102 Troglitazone is no longer available in the United States because of severe side effects, 103 which also have been observed now in another member of this drug class-rosiglitazone. 104 Therefore, until more data are available, the two available medications in this drug class should not be used for the specific treatment of NAFLD outside their use in the overall metabolic management of diabetes. Another hypoglycemic agent-metformin-has also been investigated. In the ob/ob leptin-deficient mouse model, the oral hypoglycemic agent metformin dramatically diminished hepatic steatosis. 105 Preliminary human data in three patients with NASH also showed improvement with metformin. 106 Therefore, further evaluation with this drug seems justified.
Gemfibrozil 107 at a dosage of 600 mg/d improved serum transaminases in patients with hyperlipidemia independent from weight loss. Clofibrate was shown to be ineffective in this regard.
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Specific Therapies
A number of drugs have been investigated as specific therapies for NAFLD as opposed to treatment of comorbidities.
Betaine 109 and acetylcysteine, 110 likely working as prooxidants, were effective in decreasing serum transaminases 109, 110 and improving histology 109 in preliminary reports in adult patients with NAFLD.
In children, vitamin E-a potent antioxidant 111 improved liver function tests in a series of 11 patients treated with dosages varying between 400 and 1,200 IU/d. 112 Although all three of these therapies show promise as well as the other antioxidants and anticytokine drugs listed below the broken line in Figure 5 , their routine use in NAFLD cannot be recommended at the present time until additional clinical data are available.
The drug with the most encouraging albeit nascent results thus far is ursodeoxycholic acid-a 7␤ epimer of the bile acid chenodeoxycholic acid. Three studies have shown an improved liver function tests, and one has shown improved histology. 108, 113, 114 The proposed mechanism of action of ursodeoxycholic acid has recently been reviewed in detail. 115 Available data suggest that ursodeoxycholic acid is cytoprotective, chemoprotective, and has both antioxidant and immunomodulatory properties. [116] [117] [118] The dosing pattern of ursodeoxycholic acid does not appear to be important, but a dosage of 13-15 mg/kg/d should be used. A recent study investigating the bioavailability of different ursodeoxycholic acid preparations 119 demonstrated that the Canadian preparation-Urso 250-had significantly better bioavailability than the other preparations.
A treatment algorithm is suggested in Figure 5 as a guide for the clinical management of NAFLD. Until more information is provided, it seems appropriate to treat comorbid diseases (as discussed herein) in patients with NAFLD and to implement ursodeoxycholic acid at a dosage of 13 to 15 mg/kg. The available data for treatments below the dotted line are insufficient to suggest their widespread routine use in patients with NAFLD at the present time.
Although the role of liver biopsy in patients with NAFLD remains uncertain, this author believes that patients who were found to have NAFLD on radiographic examinations should undergo liver biopsy if they are older than age 40 and have type II diabetes and/or obesity. There are three reasons for this proposal: (1) A liver biopsy yields prognostic information because the evaluation of hepatic histology is the only way to differentiate the more benign form of NAFLD-hepatic steatosis-from its more aggressive NASH form; (2) The diagnosis of NASH may provide additional motivation to patients to be compliant in the management of their comorbid diseases; and (3). It will identify those patients with NASH in whom treatment with ursodeoxycholic acid and/or antioxidants would be most justified, given the current incomplete knowledge regarding the treatment of this disease.
SUMMARY
It is important for clinicians to realize that NAFLD is the most common form of liver disease, and its prevalence will continue to increase as type II diabetes and obesity become more prevalent. There are different histologic forms of NAFLD with very different clinical outcomes. Although steatosis alone has a benign course, NASH progresses to cirrhosis and a liver-related death in 25% and 10% over 10 years, respectively.
Lipid peroxidation and inflammatory cytokines (stimulated by oxidative stress) are thought to be the major pathophysiologic mechanisms involved in NASH. Initial treatment should be to optimize the management of the comorbid diseases: type II diabetes, obesity, and hyperlipidemia. A liver biopsy provides prognostic value and can identify patients (particularly older than age 40 with either type II diabetes or obesity) who may benefit most from additional therapy with ursodeoxycholic acid and the other potential agents listed in Figure 5 . The recognition of NAFLD in children is of particular concern and emphasizes the critical need for additional studies in both the clinical and basic aspects of this disease.
